Saturday 10 October 2026 Export all IDXG data to Excel Powerpack

Interpace Biosciences, Inc.

IDXG

Interpace Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.7 million, down 17.5% from fiscal 2024. In the quarter to June 2026, revenue fell 1.09%, EPS grew 104.1% and free cash flow fell 92.1%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years.

6.00 0.00 0.00%
Market cap
—
P/E
0.2×
Fwd P/E
—
Dividend yield
—
F-score
5/9
Altman Z
−6.95
Beneish M
2.07
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Piotroski F-Score
5 7 8 4 5 4 2 3 4 —
P/E ratio
0.04 0.42 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25
Altman Z-Score
(6.95) (17.12) — — — — — — — —
P/S ratio
0.03 0.05 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02
P/FCF ratio
0.22 0.63 0.32 0.32 0.32 0.32 0.32 0.32 0.32 0.32
Altman Z″-Score (non-manufacturers)
(16.52) (47.82) (59.50) (54.04) (21.52) (19.97) (15.37) (16.44) (4.32) (12.06)
P/Operating CF
0.51 2.00 0.69 0.69 0.69 0.69 0.69 0.69 0.69 0.69
Beneish M-Score
2.07 (1.05) (2.98) (2.63) (2.98) (3.79) (2.74) (2.20) (1.70) (2.74)
P/B ratio
0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible BV
0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Sales
0.04 0.08 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04
EV/EBITDA
0.29 0.42 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25
EV/Operating CF
0.24 0.81 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50
EV/FCF
0.28 1.00 0.58 0.58 0.58 0.58 0.58 0.58 0.58 0.58
Quick Ratio
1.60 0.94 0.75 0.69 0.48 0.63 0.73 1.79 2.30 0.17
Current Ratio
1.94 1.11 0.91 0.85 0.78 0.77 0.95 2.04 2.45 0.26
Net Debt/EBITDA
(0.50) (0.16) 0.13 1.05 (7.76) 0.16 (0.03) 0.69 6.11 (3.73)
Debt/Assets
0.00% 0.00% 32.35% 85.52% 24.57% 0.00% 5.82% 0.00% 0.00% 18.93%
Debt/Equity
0.00 0.00 (0.08) (0.22) (0.22) 0.00 (0.67) 0.00 0.00 1.21
Asset Turnover
1.59 3.36 2.75 1.17 0.79 0.67 0.59 0.52 0.33 0.24
Operating CF/Net income
0.24 0.74 1.94 0.35 0.58 0.47 0.70 0.68 1.25 0.91
Capex/Depreciation
(0.40) (1.17) (0.29) (0.03) (0.06) (0.29) (3.08) (0.12) (0.01) 0.00
Interest Coverage
— 238.47 35.32 (22.89) (12.77) (47.48) (60.08) — (14.53) (3.00)
ROE
243.97% (21.60%) (3.29%) 41.63% 41.80% 175.70% (495.47%) (45.93%) (52.66%) (85.16%)
ROA
101.07% 44.70% 13.43% (80.72%) (35.53%) (60.65%) (65.73%) (29.99%) (25.62%) (15.22%)
ROIC
12.85% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% (84.19%) (15.94%) (29.10%)
Return on Tangible Assets
395.10% 247.64% (853.28%) 1,331.59% 467.11% (910.56%) (450.41%) (128.46%) (98.75%) 75.25%
Average Days of Receivables
53.24 66.46 46.30 57.69 51.49 90.44 155.80 158.08 78.91 61.62
Research and Development Expense of Revenue
1.66% 1.44% 1.59% 2.21% 4.51% 8.63% 11.60% 9.70% 9.19% 12.59%
Selling, General and Administrative Expense of Revenue
50.10% 45.05% 48.95% 63.13% 60.04% 84.72% 105.20% 78.08% 98.89% 122.02%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.05 0.06 0.43 0.47 0.40 0.62 0.87
Share Based Compensation of Revenue
0.09% 0.62% 1.57% 3.95% 3.79% 6.75% 6.34% 10.37% 6.67% 1.00%
Graham Net Nets
(1.45) (2.21) (63.65) (63.65) (63.65) (63.65) (63.65) (63.65) (63.65) (63.65)
Graham Number
125.75 0.00 0.00 208.24 144.33 171.34 69.54 0.00 0.00 0.00
Earnings Yield
2,260.62% 238.38% 406.62% 406.62% 406.62% 406.62% 406.62% 406.62% 406.62% 406.62%
Free Cash Flow Yield
461.73% 159.14% 316.22% 316.22% 316.22% 316.22% 316.22% 316.22% 316.22% 316.22%
Revenue per Share
43.77 53.48 46.37 37.56 40.04 40.21 32.33 38.88 50.42 360.47
Operating CF per Share
6.59 5.30 4.39 (9.07) (10.54) (17.35) (25.30) (15.40) (48.41) (209.56)
Capex per Share
(0.40) (1.00) (0.54) (0.38) (0.38) (1.95) (18.62) (0.80) (0.09) 0.00
Free Cash Flow per Share
6.19 4.30 3.84 (9.45) (10.92) (19.30) (43.92) (16.20) (48.50) (209.56)
Cash per Share
2.83 1.67 4.05 5.70 3.53 4.18 3.10 10.77 48.20 16.58
Shareholders Equity per Share
25.27 (2.53) (64.33) (74.41) (51.29) (36.09) (5.98) 27.43 126.45 179.92
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
25.27 (2.53) (64.33) (74.41) (51.29) (36.09) (5.98) 27.43 126.45 179.92
Free Cash Flow
5.48 3.77 3.32 (8.01) (9.03) (15.55) (32.90) (9.12) (15.29) (7.61)
Working Capital
4.80 1.16 (1.02) (2.13) (3.52) (4.11) (0.78) 9.05 11.72 (12.00)
Capital Expenditures
(0.36) (0.88) (0.47) (0.32) (0.31) (1.57) (13.95) (0.45) (0.03) —
Net Current Asset Value
(1.57) (5.24) (58.24) (66.90) (68.68) (60.64) (39.51) 2.04 6.08 (31.01)
EV/EBIT
0.35 0.46 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29
Capex to Sales
0.01 0.02 0.01 0.01 0.01 0.05 0.58 0.02 0.00 0.00
Price to Operating Income
0.27 0.29 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16
Other line items
Depreciation/Fixed assets
0.62 0.55 2.08 24.99 17.34 0.75 0.66 4.54 5.82 4.83
Cash ROIC
22.02% (498.68%) (6.94%) 17.98% 30.06% 60.50% (3,907.84%) (42.40%) (27.77%) (50.58%)
Accounts Receivable Turnover
5.46 6.89 7.92 6.56 5.22 3.53 2.44 3.39 5.63 5.22
Accounts Payable Turnover
11.05 10.62 11.55 11.23 4.86 4.70 5.51 14.06 5.42 3.42
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average Days of Payables
24.58 35.62 37.62 28.17 35.04 75.97 108.18 37.91 19.40 127.84
Days of Inventory on Hand
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average Receivables
7.10 6.81 5.06 4.85 6.35 9.18 9.91 6.46 2.82 2.51
Average Payables
1.32 1.60 1.30 1.21 2.94 4.61 2.88 0.73 1.36 1.94
Average Assets
24.32 13.95 14.55 27.20 42.05 48.61 41.33 42.36 47.69 54.75
Average Common Equity
10.07 (28.88) (59.31) (52.74) (35.75) (16.78) 5.48 27.66 23.20 9.78

Fold the line items

Columns are period end dates · fundamentals updated 28 Sep 2026